TY - JOUR AU - Maio, M. PY - 2012 DA - 2012// TI - Melanoma as a model tumour for immuno-oncology JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds257 DO - 10.1093/annonc/mds257 ID - Maio2012 ER - TY - JOUR AU - Gajewski, T. F. AU - Schreiber, H. AU - Fu, Y. X. PY - 2013 DA - 2013// TI - Innate and adaptive immune cells in the tumor microenvironment JO - Nat Immunol VL - 14 UR - https://doi.org/10.1038/ni.2703 DO - 10.1038/ni.2703 ID - Gajewski2013 ER - TY - JOUR AU - Lindau, D. PY - 2013 DA - 2013// TI - The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells JO - Immunology VL - 138 UR - https://doi.org/10.1111/imm.12036 DO - 10.1111/imm.12036 ID - Lindau2013 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Nagaraj, S. PY - 2009 DA - 2009// TI - Myeloid-derived suppressor cells as regulators of the immune system JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2506 DO - 10.1038/nri2506 ID - Gabrilovich2009 ER - TY - JOUR AU - Mougiakakos, D. PY - 2010 DA - 2010// TI - Regulatory T cells in cancer JO - Adv Cancer Res VL - 107 UR - https://doi.org/10.1016/S0065-230X(10)07003-X DO - 10.1016/S0065-230X(10)07003-X ID - Mougiakakos2010 ER - TY - JOUR AU - Mellman, I. AU - Coukos, G. AU - Dranoff, G. PY - 2011 DA - 2011// TI - Cancer immunotherapy comes of age JO - Nature VL - 480 UR - https://doi.org/10.1038/nature10673 DO - 10.1038/nature10673 ID - Mellman2011 ER - TY - JOUR AU - Jensen, I. S. PY - 2016 DA - 2016// TI - Evaluating cost benefits of combination therapies for advanced melanoma JO - Drugs Context VL - 5 UR - https://doi.org/10.7573/dic.212297 DO - 10.7573/dic.212297 ID - Jensen2016 ER - TY - JOUR AU - Loskog, A. AU - Totterman, T. H. PY - 2007 DA - 2007// TI - CD40L—a multipotent molecule for tumor therapy JO - Endocr Metab Immune Disord Drug Targets VL - 7 UR - https://doi.org/10.2174/187153007780059432 DO - 10.2174/187153007780059432 ID - Loskog2007 ER - TY - JOUR AU - Malmstrom, P. U. PY - 2010 DA - 2010// TI - AdCD40L immunogene therapy for bladder carcinoma—the first phase I/IIa trial JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-0385 DO - 10.1158/1078-0432.CCR-10-0385 ID - Malmstrom2010 ER - TY - JOUR AU - Loskog, A. PY - 2016 DA - 2016// TI - Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients JO - Br J Cancer VL - 114 UR - https://doi.org/10.1038/bjc.2016.42 DO - 10.1038/bjc.2016.42 ID - Loskog2016 ER - TY - JOUR AU - Landegren, U. PY - 2012 DA - 2012// TI - Opportunities for sensitive plasma proteome analysis JO - Anal Chem VL - 84 UR - https://doi.org/10.1021/ac2032222 DO - 10.1021/ac2032222 ID - Landegren2012 ER - TY - JOUR AU - Liljenfeldt, L. PY - 2014 DA - 2014// TI - CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes JO - Cancer Gene Ther VL - 21 UR - https://doi.org/10.1038/cgt.2014.2 DO - 10.1038/cgt.2014.2 ID - Liljenfeldt2014 ER - TY - JOUR AU - Beyer, M. AU - Schultze, J. L. PY - 2006 DA - 2006// TI - Regulatory T cells in cancer JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-02-002774 DO - 10.1182/blood-2006-02-002774 ID - Beyer2006 ER - TY - JOUR AU - Vence, L. PY - 2007 DA - 2007// TI - Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma JO - Proc Natl Acad Sci USA VL - 104 UR - https://doi.org/10.1073/pnas.0710557105 DO - 10.1073/pnas.0710557105 ID - Vence2007 ER - TY - JOUR AU - Viguier, M. PY - 2004 DA - 2004// TI - Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells JO - J Immunol VL - 173 UR - https://doi.org/10.4049/jimmunol.173.2.1444 DO - 10.4049/jimmunol.173.2.1444 ID - Viguier2004 ER - TY - JOUR AU - Sakaguchi, S. PY - 2008 DA - 2008// TI - Regulatory T cells and immune tolerance JO - Cell VL - 133 UR - https://doi.org/10.1016/j.cell.2008.05.009 DO - 10.1016/j.cell.2008.05.009 ID - Sakaguchi2008 ER - TY - JOUR AU - Jacobs, J. F. PY - 2012 DA - 2012// TI - Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70155-3 DO - 10.1016/S1470-2045(11)70155-3 ID - Jacobs2012 ER - TY - JOUR AU - Bremer, E. PY - 2013 DA - 2013// TI - Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy JO - ISRN Oncol VL - 2013 ID - Bremer2013 ER - TY - JOUR AU - Clark, J. PY - 2005 DA - 2005// TI - What does tumour necrosis factor excess do to the immune system long term? JO - Ann Rheum Dis VL - 64 ID - Clark2005 ER - TY - JOUR AU - Coussens, L. M. AU - Werb, Z. PY - 2002 DA - 2002// TI - Inflammation and cancer JO - Nature VL - 420 UR - https://doi.org/10.1038/nature01322 DO - 10.1038/nature01322 ID - Coussens2002 ER - TY - JOUR AU - Chen, X. PY - 2007 DA - 2007// TI - Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+ CD25+ T regulatory cells JO - J Immunol VL - 179 UR - https://doi.org/10.4049/jimmunol.179.1.154 DO - 10.4049/jimmunol.179.1.154 ID - Chen2007 ER - TY - JOUR AU - Tseng, H. Y. PY - 2012 DA - 2012// TI - The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells JO - Carcinogenesis VL - 33 UR - https://doi.org/10.1093/carcin/bgs236 DO - 10.1093/carcin/bgs236 ID - Tseng2012 ER - TY - JOUR AU - Ullenhag, G. J. PY - 2015 DA - 2015// TI - The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis JO - J Cancer Res Clin Oncol VL - 141 UR - https://doi.org/10.1007/s00432-014-1822-0 DO - 10.1007/s00432-014-1822-0 ID - Ullenhag2015 ER - TY - JOUR AU - Filipazzi, P. PY - 2007 DA - 2007// TI - Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.08.5829 DO - 10.1200/JCO.2006.08.5829 ID - Filipazzi2007 ER - TY - JOUR AU - Meyer, C. PY - 2014 DA - 2014// TI - Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab JO - Cancer Immunol Immunother VL - 63 UR - https://doi.org/10.1007/s00262-013-1508-5 DO - 10.1007/s00262-013-1508-5 ID - Meyer2014 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Urban, D. PY - 2011 DA - 2011// TI - CD40/CD40L interaction induces E-selectin dependent leukocyte adhesion to human endothelial cells and inhibits endothelial cell migration JO - Biochem Biophys Res Commun VL - 404 UR - https://doi.org/10.1016/j.bbrc.2010.11.142 DO - 10.1016/j.bbrc.2010.11.142 ID - Urban2011 ER - TY - JOUR AU - Orta-Mascaro, M. PY - 2016 DA - 2016// TI - CD6 modulates thymocyte selection and peripheral T cell homeostasis JO - J Exp Med VL - 213 UR - https://doi.org/10.1084/jem.20151785 DO - 10.1084/jem.20151785 ID - Orta-Mascaro2016 ER - TY - JOUR AU - Stankov, K. AU - Popovic, S. AU - Mikov, M. PY - 2014 DA - 2014// TI - C-KIT signaling in cancer treatment JO - Curr Pharm Des VL - 20 UR - https://doi.org/10.2174/13816128113199990593 DO - 10.2174/13816128113199990593 ID - Stankov2014 ER - TY - JOUR AU - Natali, P. G. PY - 1992 DA - 1992// TI - Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor JO - Int J Cancer VL - 52 UR - https://doi.org/10.1002/ijc.2910520207 DO - 10.1002/ijc.2910520207 ID - Natali1992 ER - TY - JOUR AU - Funasaka, Y. PY - 1992 DA - 1992// TI - c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas JO - Mol Biol Cell VL - 3 UR - https://doi.org/10.1091/mbc.3.2.197 DO - 10.1091/mbc.3.2.197 ID - Funasaka1992 ER - TY - JOUR AU - Zou, G. M. AU - Tam, Y. K. PY - 2002 DA - 2002// TI - Cytokines in the generation and maturation of dendritic cells: recent advances JO - Eur Cytokine Netw VL - 13 ID - Zou2002 ER - TY - JOUR AU - Pagani, E. PY - 2016 DA - 2016// TI - Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness JO - Int J Oncol VL - 48 ID - Pagani2016 ER - TY - JOUR AU - Schmidt, T. PY - 2011 DA - 2011// TI - Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia JO - Cancer Cell VL - 19 UR - https://doi.org/10.1016/j.ccr.2011.05.007 DO - 10.1016/j.ccr.2011.05.007 ID - Schmidt2011 ER - TY - JOUR AU - Gold, L. I. PY - 1999 DA - 1999// TI - The role for transforming growth factor-beta (TGF-beta) in human cancer JO - Crit Rev Oncog VL - 10 ID - Gold1999 ER - TY - JOUR AU - Moore, K. W. PY - 2001 DA - 2001// TI - Interleukin-10 and the interleukin-10 receptor JO - Annu Rev Immunol VL - 19 UR - https://doi.org/10.1146/annurev.immunol.19.1.683 DO - 10.1146/annurev.immunol.19.1.683 ID - Moore2001 ER - TY - JOUR AU - Alfaro, C. PY - 2016 DA - 2016// TI - Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs) JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2463 DO - 10.1158/1078-0432.CCR-15-2463 ID - Alfaro2016 ER - TY - JOUR AU - Waugh, D. J. AU - Wilson, C. PY - 2008 DA - 2008// TI - The interleukin-8 pathway in cancer JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4843 DO - 10.1158/1078-0432.CCR-07-4843 ID - Waugh2008 ER - TY - JOUR AU - Yuan, A. PY - 2005 DA - 2005// TI - The role of interleukin-8 in cancer cells and microenvironment interaction JO - Front Biosci VL - 10 UR - https://doi.org/10.2741/1579 DO - 10.2741/1579 ID - Yuan2005 ER - TY - JOUR AU - Bystry, R. S. PY - 2001 DA - 2001// TI - B cells and professional APCs recruit regulatory T cells via CCL4 JO - Nat Immunol VL - 2 UR - https://doi.org/10.1038/ni735 DO - 10.1038/ni735 ID - Bystry2001 ER - TY - JOUR AU - Adolfsson, J. PY - 2001 DA - 2001// TI - Upregulation of Flt3 expression within the bone marrow Lin(−)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity JO - Immunity VL - 15 UR - https://doi.org/10.1016/S1074-7613(01)00220-5 DO - 10.1016/S1074-7613(01)00220-5 ID - Adolfsson2001 ER - TY - JOUR AU - Kreiter, S. PY - 2016 DA - 2016// TI - FLT3 ligand as a molecular adjuvant for naked RNA vaccines JO - Methods Mol Biol VL - 1428 UR - https://doi.org/10.1007/978-1-4939-3625-0_11 DO - 10.1007/978-1-4939-3625-0_11 ID - Kreiter2016 ER - TY - JOUR AU - Mosley, R. L. PY - 2002 DA - 2002// TI - Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells JO - Int Immunopharmacol VL - 2 UR - https://doi.org/10.1016/S1567-5769(02)00035-8 DO - 10.1016/S1567-5769(02)00035-8 ID - Mosley2002 ER - TY - JOUR AU - Kikushige, Y. PY - 2008 DA - 2008// TI - Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival JO - J Immunol VL - 180 UR - https://doi.org/10.4049/jimmunol.180.11.7358 DO - 10.4049/jimmunol.180.11.7358 ID - Kikushige2008 ER - TY - JOUR AU - Rosborough, B. R. PY - 2014 DA - 2014// TI - Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells JO - J Immunol VL - 192 UR - https://doi.org/10.4049/jimmunol.1300058 DO - 10.4049/jimmunol.1300058 ID - Rosborough2014 ER - TY - JOUR AU - Algazi, A. P. PY - 2016 DA - 2016// TI - Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies JO - Cancer VL - 122 UR - https://doi.org/10.1002/cncr.30258 DO - 10.1002/cncr.30258 ID - Algazi2016 ER -